Positive data for PTC124, one of the first potential therapies to address the basic defect in CF were published today in The Lancet. The Phase 2 data show that treatment with PTC124 improves the function of the faulty
|
1 min read
Share this article
Topics
About the CF Foundation
|
CFTR Modulators
|
Genetic Therapies
CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug
News |
2 min read
CF Foundation Advocates to Protect Needs of People With CF in Post-Pandemic Medicaid Redeterminations
News |
5 min read
FDA Approves Kalydeco for Infants as Young as 1 Month
News |
4 min read
Stay up to date with The Foundation
Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.